Da Volterra
Da Volterra is a private, clinical-stage biopharmaceutical company founded in 2000 and headquartered in Paris, France, developing pharmaceutical innovations intended to improve health and care for people worldwide.
- Company typePrivate
- Founded2000
- HeadquartersParis, France
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Da Volterra does
Da Volterra is a clinical-stage biopharmaceutical company headquartered in Paris, France, founded in 2000. According to the firm's own positioning, the company innovates for better health and care for people worldwide, consistent with the stated mission and product strategy of European clinical-stage biopharma developers.
The company is structured around developing pharmaceutical products intended for broad patient and healthcare-system impact, though the input data does not specify a therapeutic area, lead asset, mechanism of action, modality, or pipeline stage. No platform architecture, technology stack, proprietary features, patents, or scientific publications are documented in the input; consequently, the specific scientific basis of Da Volterra's pipeline cannot be characterized from the supplied evidence.
Organizationally, Da Volterra is a private, for-profit entity led by CEO Florence Séjourné, with co-founder Antoine Andremont retained in a Scientific Advisor capacity. The input provides no information on headcount, funding history, partnerships, clinical milestones, customer relationships (not applicable pre-commercial), pricing, or revenue model. As a clinical-stage biopharma, the implied business model is one of equity-based funding of clinical development, with future commercialization via direct launch, partnership, or out-licensing — but none of these revenue mechanics are documented in the input data.
Da Volterra firmographics
Firmographics- Name
- Da Volterra
- Website
- https://davolterra.com
- Company type
- Private
- Founded year
- 2000
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Da Volterra is a private, clinical-stage biopharmaceutical company founded in 2000 and headquartered in Paris, France, developing pharmaceutical innovations intended to improve health and care for people worldwide.
- Ownership category
- akta.pro rank
Where Da Volterra is headquartered
LocationHeadquarters
- HQ city
- Paris
- HQ country
- France
- HQ region
- Europe
Markets served
Da Volterra business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
Da Volterra product offering
Product offeringCore offering
Da Volterra is a clinical-stage biopharmaceutical company that develops therapeutic products aimed at addressing antimicrobial resistance and preserving the gut microbiome during antibiotic treatments. The company focuses on innovative drug development to improve health outcomes for patients worldwide through microbiome-protective pharmaceutical solutions.
Product overview
The source data pertains to SPOTBET, an online gambling platform. No Da Volterra product information is present in the source data.
Differentiator
Problem solved
Functional benefit
Companies that use Da Volterra
Customer profileIdeal customer profiles2 records
Da Volterra technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Da Volterra partnerships and signals
Strategic signalRecent moves3 records
Expansion highlights1 record
Da Volterra competitors and assessment
Company assessmentDirect peers
- MaaT Pharma: French clinical-stage biopharmaceutical company developing microbiome-based therapeutics for oncology and gut-related diseases. It is the closest geographic and therapeutic-area peer to Da Volterra, both targeting the gut microbiome with regulated drug products.
- Seres Therapeutics: US-listed clinical-stage company developing microbiome therapeutics, including an approved C. difficile infection therapy. Directly comparable to Da Volterra on indication (CDI), mechanism (microbiome restoration), and clinical-stage business model.
- Vedanta Biosciences: Clinical-stage company developing defined bacterial consortia for recurrent C. difficile infection and other microbiome-mediated diseases. Overlaps with Da Volterra on CDI indication and microbiome-drug regulatory pathway.
- Rebiotix (Ferring Pharmaceuticals): Pioneer of live biotherapeutic products for recurrent C. difficile infection, now part of Ferring. Directly comparable to Da Volterra on therapeutic area, modality (microbiome therapeutics), and indication overlap.
- Finch Therapeutics: Clinical-stage developer of microbiome-based therapeutics including programs targeting C. difficile infection and inflammatory bowel disease. Comparable to Da Volterra on microbiome-modality and clinical-stage profile.
- Iterum Therapeutics: Clinical-stage company developing antibiotics against resistant pathogens, including oral and IV candidates targeting complicated urinary tract infections. Comparable to Da Volterra on anti-infective clinical development.
- Nabriva Therapeutics: Clinical-stage biopharma developing antibiotics for community-acquired pneumonia and other serious infections. Comparable on therapeutic area, clinical-stage model, and anti-infective commercial focus.
Emerging players
- Eligo Bioscience: Paris-based biotech developing microbiome-targeted engineered phage therapies. Comparable to Da Volterra through its Paris location, microbiome focus, and clinical-stage drug development approach, though targeting a narrower precision-microbiome niche.
Broad incumbents
- Summit Therapeutics: Clinical-stage biopharmaceutical company developing novel antibiotics for C. difficile infection and other serious infectious diseases. Comparable to Da Volterra on anti-infective therapeutic focus and clinical-stage model.
- Ferring Pharmaceuticals: Established global biopharmaceutical company with a leading microbiome franchise (Rebiotix). Comparable to Da Volterra through its CDI-treating microbiome assets and as a likely strategic acquirer of microbiome-stage companies.
Market position
Strengths3 records
Weaknesses3 records
Competitive moat2 records
Key risks5 records
Key highlights4 records
Customer concentration
Da Volterra social profiles
Digital presenceDa Volterra financial estimates
Financial estimateRevenue estimate
Valuation estimate
Da Volterra leadership team
Management profileNumber of profiles
Profiles2 records
Da Volterra funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Da Volterra M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Da Volterra
What does Da Volterra do?
Da Volterra is a clinical-stage biopharmaceutical company that develops therapeutic products aimed at addressing antimicrobial resistance and preserving the gut microbiome during antibiotic treatments. The company focuses on innovative drug development to improve health outcomes for patients worldwide through microbiome-protective pharmaceutical solutions.
When was Da Volterra founded?
Da Volterra was founded in 2000. It employs 11 to 50 people.
Where is Da Volterra based?
Da Volterra is headquartered in Paris, France, in the Europe region.
Who are Da Volterra's main competitors?
Direct peers on record are MaaT Pharma, Seres Therapeutics, Vedanta Biosciences, Rebiotix (Ferring Pharmaceuticals), Finch Therapeutics, Iterum Therapeutics and Nabriva Therapeutics. Eligo Bioscience is listed as an emerging player. Broad incumbents are Summit Therapeutics and Ferring Pharmaceuticals.
Does Da Volterra have an API?
No public API is recorded for Da Volterra.